查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863374

骨髓惡性腫瘤檢測市場：依技術、應用、最終用戶、檢體類型和檢測模式分類－2025-2032年全球預測

Hematologic Malignancies Testing Market by Technology, Application, End User, Sample Type, Test Mode - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，骨髓惡性腫瘤檢測市場將成長至 67.3 億美元，複合年成長率為 8.10%。

關鍵市場統計數據
基準年 2024 36億美元
預計年份：2025年 39億美元
預測年份 2032 67.3億美元
複合年成長率 (%) 8.10%

本書提供了一個簡潔而權威的框架，闡述了診斷創新、臨床需求和實驗室現代化如何重塑骨髓惡性腫瘤檢測路徑。

骨髓惡性腫瘤檢測處於快速發展的生物學、精準診斷和不斷變化的臨床工作流程的交匯點。分子譜分析的最新進展，以及細胞遺傳學和免疫表現型分析能力的提升，正在改變診斷路徑並深化診斷分類。隨著臨床醫生和實驗室負責人努力提供更快、更具指導意義的檢測結果，實驗室生態系統也在積極回應，建構日益整合的平台和擴充性的檢測組合，涵蓋傳統和先進的檢測方式。

因此，檢測流程不再分散，而是整合到多種診斷模式中，從而為治療方案選擇、風險分層和微量殘存疾病監測提供依據。自動化和資訊科學領域的變革性創新正在推動更高的檢測通量和更好的數據整合，同時，對品管和法規遵循的需求也在不斷影響實驗室的實施策略。總而言之，這些趨勢凸顯了當前診斷環境的特徵：臨床價值取決於分析效能、營運效率以及將複雜數據轉化為清晰治療決策點的能力。

技術融合、營運現代化和分散式檢查模式正在從根本上改變診斷實​​踐和商業性模式。

骨髓惡性腫瘤的檢測格局正經歷著變革性的轉變，這主要得益於技術的融合、臨床模式的轉變以及支付者和監管機構期望的不斷變化。分子診斷，特別是基於定序的檢測方法，正擴大與細胞遺傳學和流式細胞技術聯合應用，以產生多維度的診斷結果。同時，免疫組織化學檢測方法也在不斷改進，以適應液體和組織樣本的檢測，從而支持互補性生物標記的評估，提高診斷的準確性，並有助於標靶治療的選擇。

同時，實驗室運作正透過自動化、標準化通訊協定和雲端資料平台現代化，促進機構間的安全協作。加上血液和骨髓檢體處理技術的改進，這些變革縮短了檢測結果的獲取時間，同時提高了診斷準確性。此外，在某些情況下，就地檢驗的興起促使製造商和臨床實驗室重新思考檢測設計，以提高其穩健性和分散化程度。這些融合的趨勢正在推動新型服務模式的誕生，重塑供應商夥伴關係，並拓展基於價值的診斷策略的機會。

本文基於實證分析，探討了2025年美國已實施或提案的關稅對診斷實驗室供應鏈、採購經濟效益和業務連續性的影響。

美國擬於2025年實施或提案的關稅將對骨髓惡性腫瘤檢測價值鏈產生複雜影響，波及試劑供應、設備採購以及進口耗材的經濟效益。對診斷組件徵收關稅可能會增加檢測設備和一次性試劑的本地到貨成本，迫使採購負責人重新談判供應商合約、尋找替代貨源或加強與本地製造商的合作。因此，依賴跨境供應關係的實驗室可能需要重新評估其庫存策略，並投資於更長前置作業時間的採購計劃，以維持服務的連續性。

此外，關稅可能會加速供應鏈區域化，並鼓勵對關鍵試劑和一次性耗材的國內生產能力進行投資。然而，這種轉變需要時間和資金，而這些資源可能不足以滿足少數全球製造商生產的專用組件的需求。從監管和合約角度來看，實驗室和供應商也需要重新評估定價模式和報銷談判，以反映成本結構的變化。簡而言之，2025年的關稅趨勢將成為供應鏈多元化、營運緊急時應對計畫以及採購策略與臨床服務交付承諾更加緊密結合的催化劑。

綜合細分分析揭示了技術模式、臨床適應症、臨床環境、檢體處理流程和檢測方式如何共同作用，從而確定診斷優先順序。

基於細分市場的洞察凸顯了診斷能力與臨床需求在技術、應用領域、終端使用者、檢體類型和檢測模式等方面的交集。基於技術的診斷領域涵蓋細胞遺傳學、流式細胞技術、免疫組織化學和分子診斷。在細胞遺傳學領域，螢光原位雜合反應(FISH) 和核型分析仍是結構突變和非整倍體檢測的核心技術。同時，免疫組織化學涵蓋了用於細胞抗原分析的液相和組織學方法。分子診斷進一步細分為：用於靶向位點的螢光雜合反應、用於全面突變分析的次世代定序以及用於靈敏檢測的聚合酵素鏈鎖反應，從而形成一個支持診斷準確性的多層次套件。

應用主導的需求主要集中在白血病、淋巴瘤、多發性骨髓瘤和骨髓發育不良症候群，每種疾病都有其獨特的生物標記和監測要求，因此需要特定的檢測方法和工作流程。包括學術研究機構、醫院/診所和實驗室在內的終端用戶正在以不同的強度和規模採用這些方法，從而影響自動化和資訊整合方面的投資。檢體類型主要圍繞血液和骨髓，這決定了分析前處理和檢測方法的選擇。同時，檢測模式將工作流程分類為實驗室環境和照護現場環境，從而影響週轉時間預期和分散化策略。總而言之，這種細分分析突顯了技術選擇、臨床應用案例和醫療保健環境之間的交集，並明確了檢測方法開發、實驗室實施和商業性合作的優先事項。

一份詳細的區域評估報告，分析了基礎設施、報銷和製造能力如何推動全球市場中差異化的引入和商業化策略。

骨髓惡性腫瘤檢測的區域趨勢反映了各主要地區在醫療基礎設施、報銷機制、法規環境和創新能力方面的差異。在美洲，機構網路和參考實驗室往往主導先進分子和細胞遺傳學檢測的普及，這主要得益於競爭格局的推動，該格局強調集中式實驗室和高通量/綜合檢測組合。相較之下，歐洲、中東和非洲地區（EMEA）既有成熟的卓越中心，也存在著更為受限的環境，其檢測普及受到國家報銷政策和地區特定監管路徑的影響，因此需要量身定做的部署策略和夥伴關係模式。

亞太地區都市區正迅速採用診斷創新技術。這主要得益於臨床檢測量的成長、實驗室自動化投資的增加以及國內製造業的擴張，從而減少了對進口的依賴。在亞太地區，互通性、人才培養和供應鏈穩健性仍然是跨領域的優先事項，它們將決定新型檢測方法被納入常規臨床實踐的速度。因此，希望擴大檢測解決方案規模的相關人員必須根據每個區域市場的具體需求調整商業化、監管和支援模式，同時利用過渡性合作來加速普及和能力建設。

公司層面的策略分析表明，平台整合商、專業分子診斷創新商和服務實驗室正在重塑競爭定位和夥伴關係模式。

骨髓惡性腫瘤檢測領域的企業級趨勢顯示，成熟的診斷公司、新興的分子診斷企業和專業服務實驗室三者構成了平衡的模式。大型診斷設備製造商持續投資於平台整合、工作流程自動化和檢測項目擴展，以滿足醫院網路和高通量參考實驗室的需求。同時，規模較小的分子診斷公司則專注於小眾檢測組合、先進的定序工作流程和生物資訊能力，以推動精準醫療的應用。儀器製造商與專業試劑公司之間的策略聯盟日益普遍，由此產生的整合解決方案能夠減少操作摩擦，並加速實驗室採用這些解決方案。

服務型實驗室透過不斷擴展的檢測項目、快速的結果報告以及諮詢解讀服務來脫穎而出，從而協助臨床醫生處理複雜病例。同時，它們的商業策略強調價值驗證，顯示診斷數據如何有助於改善治療方案、減少後續資源消耗以及促進與支付者的互動。因此，那些將強大的分析能力、可靠的實施支援、本地監管專業知識和靈活的商業模式相結合的公司，更有能力滿足不同醫療機構的需求，並應對不斷變化的臨床需求。

為實驗室管理人員和診斷供應商提供切實可行的、優先排序的建議，以建立供應鏈韌性、數位整合和臨床協作，從而實現永續應用。

行業領導者應優先制定一套連貫的行動計劃，以平衡短期業務連續性和長期能力建設。首先，供應鏈多元化並與供應商密切合作將有助於降低關稅和物流風險。實驗室和供應商應攜手合作，梳理關鍵組件的依賴關係，並盡可能建立冗餘採購和本地製造夥伴關係。其次，應專注於投資自動化和資訊科學，以減少人工操作環節，並實現可擴展的解讀工作流程，整合細胞遺傳學、流式細胞技術、免疫組織化學和分子數據，從而確保臨床報告的一致性。

此外，各機構應加強與臨床實驗室的合作，以調整其檢測項目，使其適應白血病、淋巴瘤、多發性骨髓瘤和骨髓發育不良症候群不斷變化的治療模式。這將確保檢體處理和結果報告能夠滿足臨床醫生的需求。最後，採用靈活的商業模式，例如按績效付費服務、捆綁式解決方案以及基於訂閱的參考資料訪問，將有助於實驗室和供應商向支付方和醫療服務提供者展現其價值。總而言之，要維持卓越的診斷水平，有效的領導力需要在採購、技術、臨床整合和商業性創新等方面進行協調一致的投資。

本研究採用的調查方法是透明的混合方法，結合了關鍵相關人員訪談、技術檢驗和背景分析，以得出穩健、可操作的結論。

本分析的調查方法採用多源混合方法，結合了對實驗室主任、臨床專家、採購人員和行業高管的訪談，以及對監管指南、技術檢驗文獻和上市公司資訊披露的系統性回顧。數據綜合強調對供應商聲明、實驗室實踐和臨床指南進行三角驗證，以確保觀察結果反映的是實際營運情況，而非供應商的立場。定性研究結果輔以案例研究，這些案例研究涉及在血液和骨髓檢體中以及在實驗室檢測和就地檢驗模式之間部署綜合檢測策略的實驗室。

在整個研究過程中，我們始終專注於驗證有關檢測效能、檢體處理和工作流程檢驗的技術聲明，並以同行評審文獻和共識診斷框架為依據。調查方法優先考慮資訊來源的透明度，並運用結構化分析來識別發展趨勢、風險因素（例如關稅影響）以及對最終用戶（包括學術機構、醫院和參考調查方法）的實際影響。這種將相關人員的見解、技術檢驗和背景分析結合的嚴謹方法，為決策者得出切實可行的結論奠定了基礎。

簡潔扼要的結論強調了整合診斷、供應鏈韌性和策略商業化將如何決定臨床影響和營運永續性。

總之，骨髓惡性腫瘤檢測正在發展成為一個整合的多模態生態系統，細胞遺傳學、流式細胞技術、免疫組織化學和分子診斷技術在此融合，提供更豐富、更具臨床指導意義的見解。實驗室和供應商必須應對諸多挑戰，例如關稅、監管複雜性和不同地區採用模式帶來的供應鏈變化，同時還要投資於自動化、互通性和以臨床醫生為中心的報告系統。白血病、淋巴瘤、多發性骨髓瘤和骨髓發育不良症候群技術的融合和日益成長的需求，為優先考慮臨床效用和營運擴充性的差異化解決方案創造了機會。

展望未來，相關人員，將更有利於加速臨床應用。透過強調健全的採購體系、完善的檢驗流程和靈活的商業模式，產業相關人員可以將診斷技術的進步轉化為更優質的患者照護和永續的實驗室運作。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 透過整合人工智慧驅動的數位病理平台實現血液腫瘤診斷自動化
  • 利用次世代定序擴大白血病管理中微量殘存疾病監測的範圍
  • 推出液態生物檢體檢測方法
  • 開發照護現場流式細胞技術儀
  • 用於同時檢測多種骨髓惡性腫瘤標記的多重基因組檢測板的商業化
  • 監管核准流程將加速CAR-T細胞療法伴隨診斷的商業化
  • 製藥公司與診斷實驗室合作，共同開發針對血液腫瘤的標靶治療檢測方法。
  • 建立遠距病理網路，以改善資源匱乏地區獲得專業血液病理學審查服務的機會

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依技術分類的骨髓惡性腫瘤檢測市場

  • 細胞遺傳學
    • 螢光原位雜合反應
    • 核型分析
  • 流式細胞技術
  • 免疫組織化學
    • 液態
    • 組織
  • 分子診斷
    • 螢光原位雜合反應
    • 次世代定序
    • 聚合酵素鏈鎖反應

第9章 按應用分類的骨髓惡性腫瘤檢測市場

  • 白血病
  • 淋巴瘤
  • 多發性骨髓瘤
  • 骨髓發育不良症候群

第10章骨髓惡性腫瘤檢測市場（依最終用戶分類）

  • 學術和研究機構
  • 醫院和診所
  • 參考檢驗機構

第11章 依標本類型分類的骨髓惡性腫瘤檢體市場

  • 血
  • 骨髓

第12章骨髓惡性腫瘤檢測市場（依檢測方法分類）

  • 實驗室
  • 照護端

第13章 各地區骨髓惡性腫瘤檢測市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章骨髓惡性腫瘤檢測市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國骨髓惡性腫瘤檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • F. Hoffmann-La Roche AG
    • Abbott Laboratories
    • Danaher Corporation
    • Thermo Fisher Scientific Inc.
    • Becton, Dickinson and Company
    • Siemens Healthineers AG
    • QIAGEN NV
    • Illumina, Inc.
    • Bio-Rad Laboratories, Inc.
    • Myriad Genetics, Inc.
Product Code: MRR-2E76C3E47FC1

The Hematologic Malignancies Testing Market is projected to grow by USD 6.73 billion at a CAGR of 8.10% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.60 billion
Estimated Year [2025] USD 3.90 billion
Forecast Year [2032] USD 6.73 billion
CAGR (%) 8.10%

A concise and authoritative framing of how diagnostic innovation, clinical demand, and laboratory modernization are reshaping hematologic malignancy testing pathways

Hematologic malignancies testing sits at the intersection of rapidly evolving biology, precision diagnostics, and shifting clinical workflows. Recent advances in molecular profiling, coupled with enhanced cytogenetic and immunophenotyping capabilities, have transformed diagnostic pathways and deepened the granularity of diagnostic classifications. As clinicians and laboratory leaders seek to deliver faster, more actionable results, the laboratory ecosystem has responded with increasingly integrated platforms and more scalable assay portfolios that span traditional and advanced modalities.

Consequently, testing workflows are no longer siloed; they converge across multiple diagnostic modalities to inform treatment selection, risk stratification, and minimal residual disease monitoring. Transitional innovations in automation and informatics facilitate higher throughput and better data harmonization, while parallel needs for quality management and regulatory compliance continue to shape laboratory adoption strategies. Taken together, these dynamics underscore a diagnostic environment in which clinical value is driven by analytic performance, operational efficiency, and the ability to translate complex data into clear therapeutic decision points.

How technological convergence, operational modernization, and decentralized testing models are fundamentally transforming diagnostic practices and commercial approaches

The landscape for hematologic malignancies testing is experiencing transformative shifts driven by technological convergence, changing clinical paradigms, and evolving payer and regulatory expectations. Molecular diagnostics, particularly sequencing-based assays, are increasingly deployed alongside cytogenetics and flow cytometry to create multidimensional diagnostic readouts. At the same time, immunohistochemistry practices have adapted to liquid and tissue formats to support complementary biomarker assessment, enhancing diagnostic certainty and supporting targeted therapy selection.

In parallel, laboratory operations are undergoing modernization through automation, standardized protocols, and cloud-enabled data platforms that enable secure cross-institutional collaboration. Together with improvements in sample processing for blood and bone marrow, these changes reduce time to result while increasing diagnostic resolution. Moreover, the shift toward point-of-care testing in select scenarios is prompting manufacturers and clinical labs to rethink assay design for robustness and decentralization. These converging trends are catalyzing new service models, reshaping vendor partnerships, and expanding opportunities for value-based diagnostic strategies.

An evidence-based analysis of how 2025 United States tariff actions are reshaping supply chains, procurement economics, and operational resilience for diagnostic laboratories

United States tariff measures enacted or proposed in 2025 introduce complex implications for the hematologic malignancies testing value chain, affecting the economics of reagent supply, instrument procurement, and imported consumables. Tariffs on diagnostic components can increase landed costs for laboratory instrumentation and single-use reagents, which in turn pressures procurement managers to renegotiate supplier contracts, explore alternative sourcing, or accelerate local manufacturer engagement. Consequently, laboratories that rely on cross-border supply relationships may need to revise inventory strategies and invest in longer-lead planning to maintain service continuity.

Furthermore, tariffs can spur accelerated regionalization of supply chains and encourage investment in domestic manufacturing capacity for critical reagents and disposables. However, this shift requires time and capital, and it may not address specialized components produced by a limited number of global manufacturers. From a regulatory and contracting perspective, laboratories and vendors must also reassess pricing models and reimbursement negotiations to reflect altered cost structures. In short, tariff dynamics in 2025 act as a catalyst for supply chain diversification, operational contingency planning, and closer alignment between purchasing strategies and clinical service commitments.

Integrated segmentation analysis revealing how technology modalities, clinical indications, care settings, sample workflows, and testing modes align to define diagnostic priorities

Segmentation-centric insights illuminate where diagnostic capability and clinical demand intersect across technologies, applications, end users, sample types, and test modes. Based on technology, the diagnostic landscape includes cytogenetics, flow cytometry, immunohistochemistry, and molecular diagnostics; within cytogenetics, both fluorescence in situ hybridization and karyotyping remain central to structural variant and aneuploidy detection, while immunohistochemistry spans liquid-based and tissue-based approaches to cellular antigen profiling. Molecular diagnostics further breaks down into fluorescence in situ hybridization for targeted loci, next-generation sequencing for comprehensive mutational landscapes, and polymerase chain reaction for focused, high-sensitivity detection, creating a layered toolkit that supports diagnostic precision.

Application-driven demand concentrates on leukemia, lymphoma, multiple myeloma, and myelodysplastic syndromes, each presenting distinct biomarker and monitoring requirements that favor particular testing modalities and workflows. End users such as academic and research institutes, hospitals and clinics, and reference laboratories adopt these modalities with differing intensity and scale, influencing investments in automation and informatics integration. Sample type considerations center on blood and bone marrow, which dictate pre-analytical handling and assay selection, while test mode divides workflows into laboratory-based and point-of-care environments, shaping turnaround expectations and decentralization strategies. Altogether, segmentation analysis highlights where technology choices, clinical use cases, and care settings converge to define priorities for assay development, laboratory deployment, and commercial engagement.

A nuanced regional assessment detailing how infrastructure, reimbursement, and manufacturing capacity drive differentiated adoption and commercialization strategies across global markets

Regional dynamics in hematologic malignancies testing reflect differences in healthcare infrastructure, reimbursement frameworks, regulatory environments, and capacity for innovation across major geographies. In the Americas, institutional networks and reference laboratories often lead in adopting advanced molecular and cytogenetic testing, supported by centralized labs and a competitive vendor landscape that emphasizes throughput and comprehensive assay portfolios. By contrast, Europe, Middle East & Africa exhibit a heterogeneous mix of mature centers of excellence and constrained settings where adoption is influenced by national reimbursement decisions and region-specific regulatory pathways, prompting tailored rollout strategies and partnership models.

Asia-Pacific demonstrates rapid uptake of diagnostic innovation in urban centers, driven by growing clinical volumes, investments in laboratory automation, and expanding domestic manufacturing that can reduce dependence on imports. Across regions, interoperability, workforce training, and supply chain robustness remain cross-cutting priorities that determine how quickly new assays translate into routine clinical practice. Consequently, stakeholders seeking to scale testing solutions must adapt commercialization, regulatory, and support models to the nuanced needs of each geographic market while leveraging transitional collaborations to accelerate access and capability building.

Strategic company-level analysis showing how platform consolidation, specialized molecular innovators, and service labs are reshaping competitive positioning and partnership models

Company-level dynamics in hematologic malignancies testing show a balance between established diagnostics firms, emerging molecular players, and specialized service laboratories. Leading diagnostics manufacturers continue to invest in platform consolidation, workflow automation, and assay breadth to serve hospital networks and high-volume reference labs, while smaller molecular diagnostics firms focus on niche panels, advanced sequencing workflows, and bioinformatics capabilities that enable precision medicine applications. Strategic partnerships between instrument providers and reagent specialists are increasingly common, creating bundled solutions that reduce operational friction and accelerate laboratory onboarding.

Service laboratories are differentiating through expanded test menus, faster reporting, and consultative interpretive services that support clinicians in complex cases. At the same time, commercial strategies emphasize value demonstration-showing how diagnostic data improves treatment selection, reduces downstream utilization, and supports payer conversations. As a result, companies that combine robust analytical performance with strong implementation support, local regulatory expertise, and flexible commercial models are better positioned to capture demand in diverse care settings and to respond to evolving clinical needs.

Practical and prioritized recommendations for laboratory leaders and diagnostic vendors to build supply resilience, digital integration, and clinical alignment for sustained adoption

Industry leaders should prioritize a coherent set of actions that balance near-term operational continuity with long-term capability building. First, supply chain diversification and close supplier collaboration will mitigate tariff and logistics risks; laboratories and vendors should jointly map critical component dependencies and establish redundant sourcing or local manufacturing partnerships where feasible. Second, investments in automation and informatics should be targeted to reduce manual touchpoints and enable scalable interpretation workflows that integrate cytogenetic, flow, immunohistochemical, and molecular data for coherent clinical reporting.

Moreover, organizations should strengthen clinical-laboratory partnerships to align test menus with evolving treatment paradigms across leukemia, lymphoma, multiple myeloma, and myelodysplastic syndromes, ensuring that sample handling and turnaround commitments meet clinician needs. Finally, adopting flexible commercial models-such as outcome-linked services, bundled solutions, and subscription-based access to reference data-will help laboratories and vendors demonstrate value to payers and providers. In sum, actionable leadership requires coordinated investments across procurement, technology, clinical integration, and commercial innovation to sustain diagnostic excellence.

A transparent mixed-methods research approach combining primary stakeholder interviews, technical validation, and contextual analysis to ensure robust and actionable conclusions

The research methodology underpinning this analysis employed a multi-source, mixed-methods approach combining primary interviews with laboratory directors, clinical specialists, procurement leaders, and industry executives alongside a systematic review of regulatory guidance, technical validation literature, and public company disclosures. Data synthesis emphasized triangulation to reconcile supplier statements, laboratory practice patterns, and clinical guidelines, ensuring that observations reflect operational realities rather than vendor positioning. Qualitative insights were augmented by case studies that illustrate how laboratories deploy integrated testing strategies across blood and bone marrow specimens and across laboratory-based and point-of-care testing modes.

Throughout the research process, care was taken to validate technical claims regarding assay performance, sample handling, and workflow integration against peer-reviewed literature and consensus diagnostic frameworks. The methodology prioritized transparency in source attribution and applied structured analysis to identify directional trends, risk factors such as tariff impacts, and practical implications for end users including academic centers, hospitals, and reference laboratories. This rigorous combination of stakeholder insight, technical validation, and contextual analysis supports actionable conclusions for decision-makers.

A succinct conclusion emphasizing how integrated diagnostics, supply resilience, and strategic commercialization will determine clinical impact and operational sustainability

In conclusion, hematologic malignancies testing is evolving into an integrated, multimodal ecosystem where cytogenetics, flow cytometry, immunohistochemistry, and molecular diagnostics converge to provide richer, clinically actionable insights. Laboratories and vendors must navigate tariff-driven supply chain shifts, regulatory complexities, and heterogeneous regional adoption patterns while investing in automation, interoperability, and clinician-focused reporting. The convergence of technologies and growing demand across leukemia, lymphoma, multiple myeloma, and myelodysplastic syndromes create opportunities for differentiated solutions that prioritize clinical utility and operational scalability.

Looking ahead, stakeholders who align their product development, commercialization, and operational strategies with the nuanced needs of academic and research institutes, hospitals and clinics, and reference laboratories will be best positioned to accelerate clinical impact. By emphasizing resilient sourcing, robust validation, and flexible commercial models, industry players can translate diagnostic advancements into improved patient care pathways and sustainable laboratory operations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of AI-driven digital pathology platforms for automated blood cancer diagnostics
  • 5.2. Expansion of minimal residual disease monitoring using next-generation sequencing in leukemia management
  • 5.3. Adoption of liquid biopsy assays for non-invasive monitoring of treatment response in lymphoma patients
  • 5.4. Development of point-of-care flow cytometry devices for rapid immunophenotyping in resource-limited settings
  • 5.5. Commercialization of multiplexed genomic panels for simultaneous detection of multiple hematologic malignancy biomarkers
  • 5.6. Regulatory approval pathways accelerating commercialization of CAR T cell therapy companion diagnostics
  • 5.7. Partnerships between pharmaceutical companies and diagnostic labs to co-develop targeted therapy assays in blood cancers
  • 5.8. Implementation of telepathology networks to improve access to expert hematopathology review in underserved regions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hematologic Malignancies Testing Market, by Technology

  • 8.1. Cytogenetics
    • 8.1.1. Fluorescence In Situ Hybridization
    • 8.1.2. Karyotyping
  • 8.2. Flow Cytometry
  • 8.3. Immunohistochemistry
    • 8.3.1. Liquid Based
    • 8.3.2. Tissue Based
  • 8.4. Molecular Diagnostics
    • 8.4.1. Fluorescence In Situ Hybridization
    • 8.4.2. Next Generation Sequencing
    • 8.4.3. Polymerase Chain Reaction

9. Hematologic Malignancies Testing Market, by Application

  • 9.1. Leukemia
  • 9.2. Lymphoma
  • 9.3. Multiple Myeloma
  • 9.4. Myelodysplastic Syndromes

10. Hematologic Malignancies Testing Market, by End User

  • 10.1. Academic & Research Institutes
  • 10.2. Hospitals & Clinics
  • 10.3. Reference Laboratories

11. Hematologic Malignancies Testing Market, by Sample Type

  • 11.1. Blood
  • 11.2. Bone Marrow

12. Hematologic Malignancies Testing Market, by Test Mode

  • 12.1. Laboratory Based
  • 12.2. Point Of Care

13. Hematologic Malignancies Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Hematologic Malignancies Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Hematologic Malignancies Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche AG
    • 16.3.2. Abbott Laboratories
    • 16.3.3. Danaher Corporation
    • 16.3.4. Thermo Fisher Scientific Inc.
    • 16.3.5. Becton, Dickinson and Company
    • 16.3.6. Siemens Healthineers AG
    • 16.3.7. QIAGEN N.V.
    • 16.3.8. Illumina, Inc.
    • 16.3.9. Bio-Rad Laboratories, Inc.
    • 16.3.10. Myriad Genetics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. HEMATOLOGIC MALIGNANCIES TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. HEMATOLOGIC MALIGNANCIES TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HEMATOLOGIC MALIGNANCIES TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY KARYOTYPING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY KARYOTYPING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY KARYOTYPING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY KARYOTYPING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY KARYOTYPING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY KARYOTYPING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LIQUID BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LIQUID BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LIQUID BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LIQUID BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LIQUID BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LIQUID BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TISSUE BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TISSUE BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TISSUE BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TISSUE BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TISSUE BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TISSUE BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BONE MARROW, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BONE MARROW, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BONE MARROW, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LABORATORY BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LABORATORY BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LABORATORY BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LABORATORY BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LABORATORY BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LABORATORY BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-